Summit Therapeutics Share Discussion Threads

[luminoso] 18/12/2016 15:06

Just an observation - SRPT trades spiked noticeably before the death on Friday. Even little Smmt had a relatively busy end to the day !

[luminoso] 18/12/2016 15:03

Are we still led to believe that a RDZ deal does not need to wait for RDZ v FDX results, or was that only their position when we were borassic before the SRPT deal ?
Do people now assume that any RDZ deal will be after RDZ v FDX results, cos we are now flush and will get a better deal after that data presumably ?

[chrisatrdg] 17/12/2016 13:37

Per gmcc today from the other site - view re C-Diff:


'RE: Next data

Looks like Czech sites completed study according to this EMA Czech Republic link “ End of Trial Status Completed “ Date of the global end of the trial 2016-08-08 “
.


However sill ongoing on other EMA link GB sites





ClinicalTrials.gov link covers all sites Czech Republic , UK & USA ( last update 2nd August 2016 )



“This study is ongoing, but not recruiting participants “ “December 2016 (Final data collection date for primary outcome measure)”

Czech data surely available but suppose Summit will keep their powder dry until all data analysed did think at least Primary outcomes due before year end !

Good luck everyone'

Edit by chris: Per RNS this week supporting above - 'Treatment completed in exploratory Phase 2 clinical trial evaluating ridinilazole against fidaxomicin with top-line data expected to be reported in Q2 2017'

[chrisatrdg] 17/12/2016 13:18

Hi DeeJay007 I also think the timescales have changed which happened with the phase 1 results taking a year longer due to absorption issues.I am guessing recruitment is the issue this time.Hey ho.

[deejay007] 17/12/2016 12:27

Thanks Chris, thought i'd read somewhere that first results were expected in January - and found this from RNS of 17th June:

"The Company anticipates reporting data periodically during this trial with 24-week muscle biopsy data from the first group of patients enrolled expected to be reported in January 2017."

I Guess timescales have changed.

[chrisatrdg] 16/12/2016 22:05

Extraction from RNS this week - the good news is that first milestone is 'on or after 1 April 2017' $22m)but in answer to DeeJay007 its I believe covered by the second para Q2 or Q3 2017:

'Under the terms of the agreement, Summit has received an upfront payment of $40 million, and will be eligible for future ezutromid-related development, regulatory and sales milestone payments totalling up to $522 million. This includes $42 million in respect of specified development milestones (including a $22 million milestone upon the first dosing of the last patient in Summit's PhaseOut DMD trial, payable on or after 1 April 2017),'

'Enrolment of patients into PhaseOut DMD is ongoing at sites in the UK and US. The Company anticipates reporting 24-week muscle biopsy data from the first group of patients in Q2 or Q3 2017'

Link:

[deejay007] 16/12/2016 19:58

Are summit still intending initial results of DMD drug January 2017 ?

[luminoso] 16/12/2016 17:50

cheers, chrisatrdg. gambling on a turnaround on nasdaq but wtfdik.

[chrisatrdg] 16/12/2016 17:29

Well done luminso it is a brave man to Buy in the current market.I have wondered when I would Buy if I had the funds.I hope the share price now goes up.

Edit: NASDAQ final is at £1.42 trend is up.

[luminoso] 16/12/2016 16:36

For better or worse, took some at 150p.

[insideryou] 16/12/2016 09:25

Hitting new lows could be a new header

[luminoso] 15/12/2016 17:49

Ha, yes waterloo ! Strictly speaking, pre SRPT news ( ie FDA go-ahead for their drug and speculation regarding them investing in Summ ) the price was in the nineties ( pence ), where you were buying, you crafty beggar !! But, yes we are back to pre DMD deal price already. I have to say that I am ok about it as it may present a nice buying opportunity before RDZ news, which should not increase my average buying price too much. Sometimes the butterfly-brained US traders have a use.
Nice link, by the way.

[waterloo01] 15/12/2016 17:30

I wondered if $12.50 would hold but really thought $10 would. Now almost back to pre SRPT news. Go figure.

[luminoso] 15/12/2016 17:14

I think 140p is possible if no RDZ news soon. The US markets are selling off small biotechs relentlessly, cos that is what they have been told to do by the talking heads in Manhattan. So we have blue chips climbing, esp financials, and small caps being trashed.
O/T - This brave new Trump world of Goldman Sachs camped in the White House, endless talk about FED rate rises in 2017 and Trump inspired stimulus, which will never come anyway, - all fuelling the blue chip stocks rise.
Drain the swamp ? Laughing my effing head off !
Rant over.

[luminoso] 15/12/2016 13:46

Interesting to see how nasdaq reacts later. Or should I say over-reacts ? One way or the other.

[freedosh] 15/12/2016 12:09

Results out
-

"New F6 formulation of ezutromid achieved over six-fold increase in
maximum plasma levels in DMD patients compared to current F3 formulation
in Phase 1 clinical trial; F6 to be evaluated alongside F3 formulation in
ongoing PhaseOut DMD trial

-- Route to market strategy outlined that includes potential accelerated and
conditional approval pathways in the US and Europe "

[football] 15/12/2016 12:09

HIGHLIGHTS FROM RNS

Utrophin Modulation Programme for DMD

Exclusive Collaboration and License Agreement with Sarepta Therapeutics
Inc. ('Sarepta')


-- Sarepta granted exclusive European rights to Summit's utrophin modulator
pipeline including ezutromid

-- Summit received upfront payment of $40 million and is eligible to receive
up to $522 million in future ezutromid-related milestone payments plus
sales royalties

-- Global research and development costs related to ezutromid and utrophin
pipeline to be split 55%/45% (Summit/Sarepta) beginning in 2018

-- Summit is eligible to receive additional milestone payments and sales
royalties for potential future generation candidate(s)


Ezutromid Clinical Development


-- Enrolment of patients into PhaseOut DMD Phase 2 clinical trial ongoing in
the UK and US

-- New F6 formulation of ezutromid achieved over six-fold increase in
maximum plasma levels in DMD patients compared to current F3 formulation
in Phase 1 clinical trial; F6 to be evaluated alongside F3 formulation in
ongoing PhaseOut DMD trial

-- Route to market strategy outlined that includes potential accelerated and
conditional approval pathways in the US and Europe

-- Ezutromid received Fast Track designation and Rare Pediatric Disease
designation from the US Food and Drug Administration


CDI Programme


-- Preparatory activities to support ridinilazole advancing into Phase 3
clinical trials ongoing

-- Treatment completed in exploratory Phase 2 clinical trial evaluating
ridinilazole against fidaxomicin with top-line data expected to be
reported in Q2 2017


Financial Highlights


-- Cash and cash equivalents at 31 October 2016 of GBP34.6 million compared
to GBP16.3 million at 31 January 2016

-- Loss for the nine months ended 31 October 2016 of GBP16.4 million
compared to a loss of GBP13.0 million for the nine months ended 31
October 2015 (adjusted - see Note 1, 'Change in accounting policy')

[luminoso] 15/12/2016 10:52

RDZ news must be around the corner, surely ? Keep waiting for the 'obvious' bottom to top up again with my little stash, but I guess I am in danger of missing the boat if news comes in suddenly - like last time!
Not much else is tempting me, except more IMM and OPTI top ups, but frankly SUMM seems to be the best bet, regarding 'known unknowns' and 'unknown knowns', to misquote Donald Rumsfeld.
Just thinking aloud in the deafening silence.

[waterloo01] 14/12/2016 15:59

See the 21st C cures act passed yesterday.

That means our priority review voucher is safe for a couple of more years. Very few of these exist (I think 12 in total since 2009 including one for SRPT and one for Summit).

Last known sale price for one of these was $350m (only redeemable if we get approval)

[waterloo01] 13/12/2016 18:55

well we know the results will be stonking, given what went on in the quarter, so hopefully some decent headlines at least. An update would be nice.

[chrisatrdg] 12/12/2016 14:37

So true Hugus currently sitting in front a log fire with the tree up & looking forward to Christmas.As you mentioned we have been here before & provided the scientific progress continues in line with the timetable we are ok.

If the share price continues to drop maybe tempting to try & persuade the wife to invest more but the last £5K is currently 23% down.

Edit: Hopefully 9 months results this week which may invigorate the share price
Edit: Per RNS today results Thursday (no other comment).

[hugus maximus] 12/12/2016 13:12

Dreary indeed Chris. It's time to hibernate and wake up in 2017.

[chrisatrdg] 12/12/2016 13:08

Well I base my share price on Selling Price which is now £1.50 hopefully this is the bottom price.

[chrisatrdg] 10/12/2016 12:27

Hi Hugus Well put made me chuckle. Regards